Clinical trials: First Pregnancy
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Thyroid, Thyroid Dysfunction
Upper Limit for TSH of First and Second Trimester Pregnancy in Turkey
Physiological changes necessitate the use of pregnancy-specific reference ranges for TSH and FT4 to diagnose thyroid dysfunction during pregnancy.
- Conditions
- Thyroid, Thyroid Dysfunction, Hypothyroidism, Pregnancy Early
- Trial name
- NCT03754621
- Testing
- Serum thyroid functions tests
- Where
- Turkey (Türkiye)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Bartin State Hospital
Autism Spectrum Disorder, Language Delay
Implementation of Incredible Years for Autism and Language Delay Program in Spain
Children with autism spectrum disorders (ASD) usually present coexisting problems in emotion and behavior regulation, similarly as premature children with communication or socialization difficulties.
- Conditions
- Autism Spectrum Disorder, Language Delay, Prematurity
- Trial name
- FS (NCT04358484)
- Testing
- Incredible Years - ASD and Language Delay®
- Where
- Spain
- Volunteers
- 72 people
- Sponsor
- Fundació Sant Joan de Déu
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
- Trial name
- NCT06345755
- Testing
- VX-407, Midazolam
- Where
- 2 sites in United States, Canada
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Post-Partum Haemorrhage
A Clinical Trial to Study the Effectiveness of a Care Bundle to Prevent Bleeding After a Woman Has Given Birth
Every six minutes a mother dies from postpartum haemorrhage (PPH) in low-resource countries, in the prime of her life and often leaving behind a young family.
- Trial name
- E-MOTIVE (NCT04341662)
- Testing
- E-MOTIVE intervention, Usual care
- Where
- 6 sites in Kenya, Nigeria and 3 more
- Volunteers
- 99,659 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Advanced Solid Tumors, Advanced Breast Cancer
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors
- Trial name
- NCT06993844
- Testing
- ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant
- Where
- 15 sites in United States, China
- Volunteers
- 233 people
- Sponsor
- Ensem Therapeutics
Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma
- Trial name
- NCT05585034
- Testing
- XmAb®808, Keytruda® (pembrolizumab)
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Xencor, Inc.
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Ovarian Cancer, Peritoneal Cancer
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT07743164
- Testing
- R-DXd, Bevacizumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 646 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
To Observe and Evaluate the Efficacy and Safety of Apatinib in Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.
- Trial name
- NCT03546855
- Testing
- Apatinib
- Volunteers
- 69 people
- Sponsor
- Anhui Provincial Hospital
Polycystic Ovary Syndrome
Sebum Excretion in Neonates of Women With Polycystic Ovary Syndrome (PCOS)
To investigate whether women with polycystic ovary syndrome who are post-partum excrete higher levels of sebum in comparison to healthy controls due to high levels of androgens.
- Trial name
- NCT02654548
- Testing
- Sebutape
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Homerton University Hospital NHS Foundation Trust
Ovarian Cancer, HRD
Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients
Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer.
- Conditions
- Ovarian Cancer, HRD, PARP Inhibitor
- Trial name
- HOPEI (NCT05044091)
- Testing
- PARP inhibitor
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xiaoxiang Chen
NSCLC, SCLC
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.
- Conditions
- NSCLC, SCLC, CRPC, ESCC
- Trial name
- NCT04686682
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Abnormal Uteroplacental Circulation
Study on Doppler Ultrasound Measurement of Changes in Uterine Artery Blood Flow in Normal First Trimester Pregnancies and Its Prediction on Abortion
Objective:To explore the study of Doppler ultrasound in first trimester pregnancies to measure the change of uterine artery blood flow in normal pregnancies and the prediction on abortion, which provides a certain reference for…
- Trial name
- NCT06043804
- Testing
- Doppler ultrasound measurement of changes in uterine artery blood flow
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Abortifacient Agents, Nonsteroidal, Abortion, Incomplete
Misoprostol for Non-Viable Pregnancies
The purpose of this study is to examine the effectiveness of Misoprostol (Cytotec; GD Searle and Co., Chicago, IL) for the management of non-viable first trimester pregnancies.
- Conditions
- Abortifacient Agents, Nonsteroidal, Abortion, Incomplete, Misoprostol, Pregnancy
- Trial name
- NCT00426491
- Testing
- Misoprostol
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Madigan Army Medical Center
Kidney Diseases, Kidney Transplant; Complications
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in…
- Conditions
- Kidney Diseases, Kidney Transplant; Complications, COVID-19, Vaccine Adverse Reaction
- Trial name
- NCT05483725
- Testing
- Booster dose of mRNA vaccine
- Where
- Czechia
- Volunteers
- 108 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers.
- Conditions
- Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02729298
- Testing
- TP-0903
- Where
- 16 sites in United States
- Volunteers
- 177 people
- Sponsor
- Sumitomo Pharma America, Inc.
Cesarean Section Complications, Blood Loss, Surgical
Tranexamic Acid Versus Misoprostol in Reducing Blood Loss in Cesarean Section in Primigravida
The aim of the work is to compare the efficacy of preoperative IV tranexamic acid and rectal misoprostol in reducing blood loss in the elective cesarean section.
- Conditions
- Cesarean Section Complications, Blood Loss, Surgical, Misoprostol, Tranexamic Acid
- Trial name
- NCT04635007
- Testing
- Tranexamic acid, Misoprostol 200mcg Tab
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Cairo University
Stage IVB Cervical Cancer, Recurrent Cervical Cancer
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Cervical cancer is the second-most common cancer in the world and is a leading cause of cancer death among women in developing countries.
- Conditions
- Stage IVB Cervical Cancer, Recurrent Cervical Cancer, Persistent Cervical Cancer
- Trial name
- NCT04974944
- Testing
- Camrelizumab, Apatinib, Paclitaxel
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-Sen University Cancer Center
KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors…
- Conditions
- KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
- Trial name
- NCT07458347
- Testing
- KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab
- Where
- 9 sites in United States
- Volunteers
- 545 people
- Sponsor
- Kestrel Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.